Cognitive Impairment Mechanisms in Alzheimer’s Disease Models

Alzheimer’s disease (AD) models have elucidated a multifactorial cascade leading to cognitive decline. Central to this is the accumulation of oligomeric amyloid-β and hyperphosphorylated tau, which disrupt synaptic plasticity and provoke neuronal loss. Synaptic dysfunction emerges early, characterised by impaired long-term potentiation and reduced neurotransmitter release, often exacerbated by disruptions in insulin signalling and glucose metabolism. Mitochondrial dysfunction contributes to energy deficits and oxidative stress, further compromising synaptic integrity. Concurrently, chronic neuroinflammation—driven by activated microglia and astrocytes—amplifies neuronal damage through cytokine release and phagocytic activity. Autophagic pathways, normally responsible for clearing misfolded proteins and damaged organelles, become dysregulated, allowing toxic species to accumulate. Experimental models that recapitulate these features, including transgenic lines and intracerebroventricular streptozotocin administration, have been instrumental in mapping these interconnected mechanisms. Together, they delineate a network in which proteostatic failure, metabolic insufficiency and inflammatory signalling converge to impair cognition, providing multiple targets for therapeutic intervention.

Research from Nature Portfolio

Daily intranasal insulin administration in a streptozotocin-induced rat model was shown to reverse memory deficits in the Morris water maze and restore synaptic markers. Treatment attenuated tau hyperphosphorylation by down-regulating ERK1/2 and CaMKII kinases and reduced microglial activation in hippocampal subregions. Neurogenesis was enhanced, suggesting that enhancing central insulin signalling may ameliorate early synaptic and metabolic disturbances that underlie cognitive impairment.

Cognitive Impairment Mechanisms in Alzheimer’s Disease Models publication trend

The graph below shows the total number of articles in cognitive impairment mechanisms in alzheimer’s disease models across all publications each year (not limited to Nature Index journals).

Technical terms

Oligomeric amyloid-β: Small soluble aggregates of amyloid-β peptides that impair synaptic transmission.

Tau hyperphosphorylation: Excessive addition of phosphate groups to tau protein, leading to microtubule destabilisation.

Synaptic plasticity: The ability of synapses to strengthen or weaken in response to activity, essential for learning and memory.

Neuroinflammation: Chronic activation of glial cells and release of cytokines that exacerbate neuronal injury.

Mitochondrial dysfunction: Impaired energy production and increased oxidative stress within neurons.

Intracerebroventricular streptozotocin (ICV-STZ): A chemical method to induce brain insulin resistance and AD-like pathology in rodents.

Autophagy: A cellular degradation process that clears damaged proteins and organelles to maintain homeostasis.

References

1. Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer’s rat model. Scientific Reports (2017).
2. Pirh2 modulates the mitochondrial function and cytochrome c-mediated neuronal death during Alzheimer’s disease. Cell Death & Disease (2024).
3. Proteomic Analysis of a Rat Streptozotocin Model Shows Dysregulated Biological Pathways Implicated in Alzheimer’s Disease. International Journal of Molecular Sciences (2024).
4. Melatonin improves cognitive dysfunction and decreases gliosis in the streptozotocin-induced rat model of sporadic Alzheimer’s disease. Frontiers in Pharmacology (2024).